The Bicycle® platform is highly flexible for molecular design. Bicycles® can be developed to modulate single targets as stand-alone therapeutics (Bicycles®), to combine effector functions where two Bicycles are coupled together (bi-specific Bicycles®), or to deliver other molecular cargos (Bicycle Drug Conjugates® or BDCs, Bicycle Therapeutics’ initial focus).
One advantage of identifying Bicycles® attached to a large phage particle is that this “molecular bulk” can be removed and used as a point of attachment for other functional entities without affecting the binding affinity of the molecule and can also be leveraged to optimize pharmacokinetics. Some of these applications of the Bicycle® technology are illustrated below.
BICYCLES® CAN BE USED AS SIMPLE UNELABORATED STRUCTURES AS A NEW CLASS OF THERAPEUTICS
BICYCLES® CAN ALSO BE USED TO GENERATE MORE COMPLEX MOLECULES
BICYCLES® CAN BE USED IN COMBINATION, OR WITH OTHER MOLECULAR CARGOES, TO DELIVER ADDITIONAL FUNCTIONALITY
Bicycle Therapeutics’ initial focus is on BDCs that selectively deliver toxins to tumours. The company is looking to explore its technology outside of BDCs through partnerships, as exemplified by its existing collaboration with ThromboGenics in ophthalmology.